Related Experiment Video
Updated: Aug 7, 2026
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Reduction in chronic allograft nephropathy by inhibition of p38 mitogen-activated protein kinase
Takashi Wada1, Haruhito Azuma, Kengo Furuichi
1Department of Gastroenterology and Nephrology, Graduate School of Medical Science, Kanazawa University, Takara-machi, Kanazawa, Japan. twada@medf.m.kanazawa-u.ac.jp
Background:
Chronic allograft nephropathy (CAN) is the major cause for late graft loss and is therefore a key target for therapy.
Methods:
The impact of p38 mitogen-activated kinase (MAPK) on CAN was investigated by administering FR167653 (32 mg/kg/day), a specific inhibitor of p38 MAPK, for 4 weeks in addition to conventional cyclosporine therapy (1.5 mg/kg/day for 5 days) in an established experimental rat transplantation model.
Results:
Transplanted rats develop glomerulosclerosis, arterial obliteration, interstitial fibrosis and tubular atrophy, all of which are characteristic of CAN, resulting in shortened survival on 32 weeks. However, the inhibition of p38 MAPK by daily subcutaneous treatment with FR167653 resulted in reduced CAN with preserved renal function and prolonged survival. The FR167653-treated rats had fewer phosphorylated p38 MAPK-positive cells in treated kidneys. Concomitantly, the expression of monocyte chemoattractant protein-1/CCL2 and transforming growth factor-beta(1) was markedly reduced.
Conclusion:
These results suggest that p38 MAPK phosphorylation is involved in the pathogenesis of CAN and provide evidence that p38 MAPK is a novel, appealing therapeutic target for combating CAN.
Insights
Inhibiting p38 mitogen-activated kinase (MAPK) with FR167653 in rats reduced chronic allograft nephropathy (CAN) and prolonged survival. This suggests p38 MAPK is a promising therapeutic target for preventing late graft loss.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Chronic allograft nephropathy (CAN) is a primary cause of late kidney transplant loss.
- Effective therapies are crucial to improve long-term graft survival.
Purpose of the Study:
- To investigate the role of p38 mitogen-activated kinase (MAPK) in the development of CAN.
- To evaluate the therapeutic potential of a p38 MAPK inhibitor, FR167653, in a rat transplantation model.
Main Methods:
- An established rat kidney transplantation model was used.
- Rats received cyclosporine plus either FR167653 (p38 MAPK inhibitor) or a vehicle control.
- Renal function, graft survival, and histological markers of CAN were assessed.
Main Results:
- FR167653 treatment significantly reduced glomerulosclerosis, fibrosis, and tubular atrophy characteristic of CAN.
- Inhibition of p38 MAPK led to preserved renal function and prolonged survival in transplanted rats.
- Reduced p38 MAPK phosphorylation and lower expression of inflammatory markers (CCL2, TGF-β1) were observed in treated kidneys.
Conclusions:
- p38 MAPK phosphorylation plays a significant role in the pathogenesis of CAN.
- Targeting p38 MAPK with inhibitors like FR167653 represents a novel therapeutic strategy for combating CAN.
- This study provides evidence for p38 MAPK as a viable target to prevent chronic allograft damage and improve transplant outcomes.